<code id='50EEBB917B'></code><style id='50EEBB917B'></style>
    • <acronym id='50EEBB917B'></acronym>
      <center id='50EEBB917B'><center id='50EEBB917B'><tfoot id='50EEBB917B'></tfoot></center><abbr id='50EEBB917B'><dir id='50EEBB917B'><tfoot id='50EEBB917B'></tfoot><noframes id='50EEBB917B'>

    • <optgroup id='50EEBB917B'><strike id='50EEBB917B'><sup id='50EEBB917B'></sup></strike><code id='50EEBB917B'></code></optgroup>
        1. <b id='50EEBB917B'><label id='50EEBB917B'><select id='50EEBB917B'><dt id='50EEBB917B'><span id='50EEBB917B'></span></dt></select></label></b><u id='50EEBB917B'></u>
          <i id='50EEBB917B'><strike id='50EEBB917B'><tt id='50EEBB917B'><pre id='50EEBB917B'></pre></tt></strike></i>

          Home / knowledge / knowledge

          knowledge


          knowledge

          author:fashion    Page View:119
          Blood corpuscles in clot
          Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success. David Gregory & Debbie Marshall/Wellcome Images

          Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success.

          LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries. The tool is meant only for patients with a severe form of peripheral artery disease, and who have already tried more conservative options.

          advertisement

          Dan Rose, CEO of LimFlow, previously told STAT that his mission is to fight the amputation epidemic in the United States, which disproportionately impacts Black patients. Experts cautioned to STAT that expanding screenings to catch the disease early is still the most important measure.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In